Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity

Significance: A high-throughput pipeline using multiplex immunofluorescence in pancreatic cancer reveals striking expression subtype intratumoral heterogeneity with implications for therapy selection and identifies co-expressor cells that may serve as intermediates during subtype switching.

Citing Articles

A novel signature predicts prognosis in pancreatic cancer based on tumor membrane-associated genes.

Ding Z, Wu J, Ye Y, Zhong Y, Yan L, Wang P Heliyon. 2025; 11(4):e42791.

PMID: 40066030 PMC: 11891719. DOI: 10.1016/j.heliyon.2025.e42791.

Advances in Vaccine-Based Therapies for Pancreatic Cancer.

McMillan M, Soares K J Gastrointest Cancer. 2025; 56(1):62.

PMID: 39939414 PMC: 11821674. DOI: 10.1007/s12029-025-01165-4.

Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach.

Hilmi M, Delecourt F, Raffenne J, Bourega T, Dusetti N, Iovanna J J Pathol. 2025; 265(4):448-461.

PMID: 39935174 PMC: 11880971. DOI: 10.1002/path.6398.

SMAD4 and KRAS Status Shape Cancer Cell-Stromal Crosstalk and Therapeutic Response in Pancreatic Cancer.

Lloyd E, Jihad M, Manansala J, Li W, Cheng P, Mucciolo G Cancer Res. 2025; .

PMID: 39841099 PMC: 7617379. DOI: 10.1158/0008-5472.CAN-24-2330.

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.

Klein L, Tu M, Krebs N, Urbach L, Grimm D, Latif M Nat Commun. 2025; 16(1):335.

PMID: 39762215 PMC: 11704331. DOI: 10.1038/s41467-024-55330-7.

References

Grunwald B, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey C . Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021; 184(22):5577-5592.e18. DOI: 10.1016/j.cell.2021.09.022. View

Nicolle R, Blum Y, Duconseil P, Vanbrugghe C, Brandone N, Poizat F . Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. EBioMedicine. 2020; 57:102858. PMC: 7334821. DOI: 10.1016/j.ebiom.2020.102858. View

Roa-Pena L, Leiton C, Babu S, Pan C, Vanner E, Akalin A . Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci Rep. 2019; 9(1):11239. PMC: 6677817. DOI: 10.1038/s41598-019-47519-4. View

Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C . Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019; 14(1):141. PMC: 6688256. DOI: 10.1186/s13014-019-1345-6. View

Aguirre A, Nowak J, Camarda N, Moffitt R, Ghazani A, Hazar-Rethinam M . Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018; 8(9):1096-1111. PMC: 6192263. DOI: 10.1158/2159-8290.CD-18-0275. View

Moffitt R, Marayati R, Flate E, Volmar K, Loeza S, Hoadley K . Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015; 47(10):1168-78. PMC: 4912058. DOI: 10.1038/ng.3398. View

Zeng Y, Zou M, Liu Y, Que K, Wang Y, Liu C . Keratin 17 Suppresses Cell Proliferation and Epithelial-Mesenchymal Transition in Pancreatic Cancer. Front Med (Lausanne). 2020; 7:572494. PMC: 7726264. DOI: 10.3389/fmed.2020.572494. View

Vayrynen S, Zhang J, Yuan C, Vayrynen J, Dias Costa A, Williams H . Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clin Cancer Res. 2020; 27(4):1069-1081. PMC: 8345232. DOI: 10.1158/1078-0432.CCR-20-3141. View

Rakha E, Pinder S, Bartlett J, Ibrahim M, Starczynski J, Carder P . Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2014; 68(2):93-9. PMC: 4316916. DOI: 10.1136/jclinpath-2014-202571. View

10.

Kalimuthu S, Wilson G, Grant R, Seto M, OKane G, Vajpeyi R . Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome. Gut. 2019; 69(2):317-328. DOI: 10.1136/gutjnl-2019-318217. View

11.

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018; 142(11):1364-1382. DOI: 10.5858/arpa.2018-0902-SA. View

12.

Chen W, Frankel W . A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol. 2019; 32(Suppl 1):1-15. DOI: 10.1038/s41379-018-0136-1. View

13.

Chan-Seng-Yue M, Kim J, Wilson G, Ng K, Figueroa E, OKane G . Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020; 52(2):231-240. DOI: 10.1038/s41588-019-0566-9. View

14.

Topham J, Karasinska J, Lee M, Csizmok V, Williamson L, Jang G . Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Clin Cancer Res. 2020; 27(1):150-157. DOI: 10.1158/1078-0432.CCR-20-2831. View

15.

Qian Z, Rubinson D, Nowak J, Morales-Oyarvide V, Dunne R, Kozak M . Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2017; 4(3):e173420. PMC: 5844844. DOI: 10.1001/jamaoncol.2017.3420. View

16.

Duan K, Jang G, Grant R, Wilson J, Notta F, OKane G . The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Sci Rep. 2021; 11(1):14951. PMC: 8298486. DOI: 10.1038/s41598-021-94544-3. View

17.

Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K . Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019; 16(12):1289-1296. PMC: 6884693. DOI: 10.1038/s41592-019-0619-0. View

18.

Rashid N, Peng X, Jin C, Moffitt R, Volmar K, Belt B . Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Clin Cancer Res. 2019; 26(1):82-92. PMC: 6942634. DOI: 10.1158/1078-0432.CCR-19-1467. View

19.

Bailey P, Chang D, Nones K, Johns A, Patch A, Gingras M . Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52. DOI: 10.1038/nature16965. View

20.

Choudhary S, Satija R . Comparison and evaluation of statistical error models for scRNA-seq. Genome Biol. 2022; 23(1):27. PMC: 8764781. DOI: 10.1186/s13059-021-02584-9. View